On January 14, 2009, Genta Incorporated, (the Company), announced it has initiated a new clinical trial with tesetaxel, the latest addition to Genta's oncology product portfolio. Unlike standard taxanes such as paclitaxel (Taxol�), which must be infused intravenously, tesetaxelis administered by mouth as a capsule. The new study will examine the clinical pharmacology of the drug over a narrow dosing range around the established Phase 2 dose. As a late Phase 2 agent, the Company believes tesetaxel is the leading oral taxane currently in clinical development.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.